Cercare Medical is pleased to announce our participation in the world’s largest medical imaging forum, RSNA 2024, which will be held in Chicago, USA, from December 1-4. This prestigious event brings together industry leaders, professionals, and innovators from around the globe to explore the latest advancements in medical imaging technology.
As experts unite to discuss developments in perfusion imaging, we believe this is the perfect venue for Cercare Medical to showcase our latest offering: the Cercare Medical Neurosuite 16.0. Our advanced platform highlights our unique biomarkers that are paving the way in introducing Metabolic Perfusion Imaging.
Be one of the first to experience the pre-release version of CMN 16.0
Cercare Medical Booth # 7801, North Hall 3
Date: Dec 1 – 4, 2024
Venue: McCormick Center
Location: Chicago, Illinois, USA
We invite you to learn about our technology and meet our team. Our founder, Professor Kim Mouridsen, will also be available to discuss how this innovation is transforming the field of Perfusion Imaging.
For a more personalized experience, we encourage you to book your spot with our experts.
We are hosting an exclusive event on December 2 at the Marriott Hotel, focusing on deep-dive discussions in the field of Stroke and Neuro-Oncology. Don’t miss this opportunity to engage in insightful conversations with top professionals including Dr. Alexandre Bani-Sadr, MD, PhD, who has just published a paper about "Oxygen Extraction Fraction Mapping" in the November 2024 issue of Stroke.
Date: Dec 2, 2024
Venue: George Pullman, Marriott Hotel
Time: 6:00 – 8:00pm
Limited slots available—reserve your place now for an immersive experience with our newest advancements.
Cercare Medical is a provider of advanced perfusion imaging solutions. With fully automated and multi-vendor compatible software for CT and MRI perfusion imaging post-processing, we are committed to delivering cutting-edge technology that enhances patient care and advances medical diagnostics across various neurological conditions, including Stroke, Oncology, Alzheimer's, Dementia, and COVID-19. Our proprietary biomarkers allow for better, more precise imaging maps, improving decision-making in critical care and enhancing neuroimaging. This innovative technology has led to widespread adoption by leading hospitals and clinics around the world.
